摘要
目的观察阿托伐他汀治疗冠状动脉粥样硬化性心脏病的效果。方法选取患者72例,随机分为对照组和治疗组,各36例。两组均常规给予阿司匹林、波立维、硝酸酯类、血管紧张素转换酶抑制剂及钙拮抗剂等药物治疗。治疗组在此基础上给予阿托伐他汀联合治疗。结果与对照组比较,治疗组脉压差下降明显,有显著性差异(P<0.05);治疗8周后,治疗组患者血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平明显降低,而高密度脂蛋白胆固醇(HDL-C)水平明显升高,与对照组比较有显著性差异(P<0.05);治疗组患者血清炎性因子水平与对照组比较明显下降,有显著性差异(P<0.05)。两组患者住院期间心律失常等心脑血管事件的发生情况比较,有显著性差异(P<0.05)。结论在常规治疗的基础上,联合应用阿托伐他汀治疗冠状动脉粥样硬化性心脏病,疗效显著,安全可靠。
Objective To observe the effects of atorvastatin in the treatment of coronary arteriosclerotic heart disease. Methods Seventy- two patients with coronary arteriosclerotic heart disease were selected and randomly divided into the control group and the treatment group, 36 cases in each group. The two groups were routinely given aspirin, Plavix, nitrates, ACEI, calcium antagonists and other drugs. On this basis, the treatment group was given the combination therapy of atorvastatin. Results The pulse pressure in the treatment group was decreased more significant than that in the control group with statistical difference between 2 groups（ P 〈 0. 05）; after 8 weeks treatment, the levels of serum total cholesterol （TC） and low-density lipoprotein cholesterol （LDL-C） were significantly decreased, while the level of serum high-density lipoprotein cholesterol （HDL-C） was significantly increased, which showing statistical difference com- pared with the control group（ P 〈 0. 05）; the levels of serum inflammatory factors in the treatment group were obviously decreased compared with the control group, with statistical difference between 2 groups（ P〈 0.05）. Arrhythmia and other cardiovascular events during hospitalization were significantly different between 2 groups（ P 〈 0. 05）. Conclusion In the basis of conventional treatment, combination use of atorvastatin is significantly effective, safe and reliable in treating coronary arteriosclerotic heart disease.
出处
《中国药业》
CAS
2012年第17期61-62,共2页
China Pharmaceuticals
